Highlight Therapeutics Overview
Latest Deal Type
Later Stage VC
Highlight Therapeutics General Information
Description
Developer of RNA-based therapies intended to treat cancer. The company's therapies recapitulate the effect of viral infection and enhance the therapeutic effect of drugs, enabling physicians to induce immunogenic cell death in solid tumors.
Want to dig into this profile?
We’ll help you find what you need
Learn more
Highlight Therapeutics Valuation & Funding
| Deal Type |
Date |
Amount |
Raised to Date |
Post-Val |
Status |
Stage |
| 4. Later Stage VC |
|
|
|
|
Completed |
Clinical Trials - Phase 2 |
| 3. Grant |
|
|
|
|
Completed |
Pre-Clinical Trials |
| 2. Later Stage VC |
06-Oct-2016 |
|
|
|
Completed |
Pre-Clinical Trials |
| 1. Accelerator/Incubator |
01-Jan-2010 |
|
|
|
Completed |
Pre-Clinical Trials |
Highlight Therapeutics Executive Team (4)
| Name |
Title |
Board Seat |
Contact Info |
| Marisol Quintero Ph.D |
Chief Executive Officer |
|
|
| Mercedes Pozuelo Rubio Ph.D |
Chief Operating Officer |
|
|
| Damià Tormo Ph.D |
Co-Founder & Board Member |
|
|
| Dominique Tersago MD |
Chief Medical Officer |
|
|